Commission and EIB provide CureVac with a €75 million financing for vaccine development and expansion of manufacturing

vaccinations CDC

(CDC, Unsplash)

This article is brought to you in association with the European Commission.


  • European Investment Bank and CureVac sign €75 million loan agreement for the development and large-scale production of vaccines, including CureVac’s vaccine candidate against SARS-CoV-2
  • The EIB loan will support CureVac’s activities to complete its new messenger ribonucleic acid (mRNA) production facility in Tübingen, Germany
  • The transaction is financed under the Infectious Diseases Finance Facility of Horizon 2020, the EU research and innovation programme for 2014-2020

The European Investment Bank (EIB) and CureVac, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimised mRNA, entered into a €75 million loan agreement to support the Company’s ongoing development of vaccines against infectious diseases, including its vaccine candidate CVnCoV aimed at preventing SARS-CoV-2 infections. In addition, the loan will support the Company’s efforts to expand its existing Good Manufacturing Practice (GMP) certified production capabilities and accelerate the completion of its fourth production site in Tübingen, Germany. The EIB financing will be provided in three €25 million tranches upon completion of pre-defined milestones.

Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth, said: “The coronavirus will be with us, as long as we do not have a vaccine against it. This is why our work on this front, together with international actors, is so crucial. Recently we have presented our vaccines strategy to accelerate the development, manufacturing and deployment of vaccines against the novel coronavirus. And since the beginning of the pandemic, we increased the funding for the Infectious Diseases Finance Facility by €400 million to allow the EIB to process a higher volume of projects addressing this disease. With our support to CureVac we accelerate our efforts to find safe and effective solutions for everyone in Europe and globally.”

It does not need a pandemic to prove that new vaccines can be breakthroughs for public health,” said Ambroise Fayolle, EIB Vice-President in charge of innovation and health. “But in times like ours it becomes clear just how important they are to keep societies running globally. In fact, the only way to end the dramatic situation the world is facing since the outbreak of the COVID-19 pandemic would be a safe and effective vaccine. Thanks to our cooperation with the European Commission, we can finance more and more innovative biotech and medtech companies, such as CureVac, in their research and development of vaccines, therapeutics and diagnostics solutions. This is an added value of Europe, and the EIB does everything it can to maximise this value for the sake of people.”

Pierre Kemula, Chief Financial Officer of CureVac, added: “We are very pleased with the EIB financing. It allows us to further invest in our mRNA technology platform to fight life-threatening diseases. We are working intensively to develop a safe and effective low dose mRNA vaccine against SARS-CoV-2 and started a Phase 1 clinical trial of CVnCoV in June. We are looking forward to expediting the completion of our industrial-scale production site to provide critically needed supply of innovative mRNA-based vaccines.”

About CureVac’s mRNA technology platform

CureVac’s mRNA technology platform has shown potential in the clinical development and production of mRNA based vaccines and therapeutics. The Company’s proprietary RNAoptimizer® platform aims to optimize the properties of mRNA medicines based on its three core pillars: protein design, mRNA optimization and mRNA delivery. The technology can be tailored to induce varying degrees of immune responses against specific protein antigens of choice, potentially providing potent prophylactic vaccines for the prevention of infectious diseases at a low dose, such as Rabies, as well as immunotherapies for the treatment of cancer. The technology can also be adapted to avoid immune activation for purposes of protein therapy and antibodies, thereby providing potential new therapeutic modalities for patients suffering from a vast range of diseases.

The Infectious Diseases Finance Facility (IDFF) of the EU’s Horizon 2020 programme backs the loan to CureVac. The IDFF is an example of successful collaboration between the European Commission and the EIB in the face of a health crisis. Through the IDFF, the EIB has supported 13 companies with total lending of €316 million for developing cures, vaccines and diagnostics against various infectious diseases, most prominently the coronavirus.

 

Background

The European Investment Bank is the long-term lending institution of the European Union owned by its Member States. It makes long-term finance available for sound investments in order to contribute towards EU policy goals. The EIB also supports investments outside the EU.

The InnovFin Infectious Diseases Finance Facility (IDFF) is a financial product dedicated to support the fight against infectious diseases. The joint European Commission and EIB Group initiative falls under Horizon2020, the 2014-2020 EU research and innovation programme. IDFF enables the EIB to provide between €7.5 million and €75 million of funding to innovative players active in developing vaccines, drugs, medical and diagnostic devices and research infrastructure for combatting infectious diseases. The loans finance clinical trials, market access, and the development of prototypes or industrial roll out of novel equipment, pre-clinical R&D and working capital needs. The IDFF has been reinforced by €400 million to better tackle the outbreak of COVID-19.

CureVac is a leading clinical stage biotechnology company in the field of messenger RNA (mRNA) technology with 20 years of expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

6 ways countries can prepare for the next infectious disease pandemic

Moves to create a Kosovo army have ‘deteriorated relations’ with Serbia: UN peacekeeping chief

Smart city experts should be looking to emerging markets. Here’s why

3 unexpected consequences of the US-China trade war

China and China-EU Relations in the New Era

Beyond ‘business as usual’. Addressing the climate change crisis

Eurozone at risk of home-made deflation and recession

We need to give voice to ‘We the Peoples’, says UN chief

With Libyans now ‘fighting the wars of others’ inside their own country, UN envoy urges Security Council action to end violence

German stock market is not affected by the Greek debt revolution while Athens is running out of time

Coronavirus: EU guidance for a safe return to the workplace

5 things COVID-19 has taught us about inequality

Pharmaceuticals: Commission refines intellectual property rules

All States have ‘primary responsibility’ to protect against hate attacks

How the ‘California effect’ could shape a global approach to ethical AI

South Korea: A cherished partner for the EU

Where is heading Putin’s Russia?

New Mozambique storm rips off roofs, brings lashing rain as aid response kicks in

UN refugee agency presses States to aid 49 refugees stranded on Mediterranean

Young translators at EU schools – Commission opens registration for 2020 translation contest

Negotiated two-State solution still ‘the only option’ for Palestine: Guterres

UN political chief calls for dialogue to ease tensions in Venezuela; Security Council divided over path to end crisis

State aid: Commission approves €1.2 billion French “Fonds de solidarité” scheme for small enterprises in temporary financial difficulties due to coronavirus outbreak

These are the top 10 global causes of death – but two diseases are in decline

Brazilian health: right or privilege?

Why the minutes and the months matter most to young people during the COVID-19 crisis

Stop cooperation with and funding to the Libyan coastguard, MEPs ask

Statement by the European Commission following the extraordinary meeting of the EU-UK Joint Committee

Why Eurozone urgently needs the ECB to print and distribute at least €500 billion

The remote doctor in the 21st century

Over 820 million people suffering from hunger; new UN report reveals stubborn realities of ‘immense’ global challenge

“France will be there, it will always be there!”, French President Hollande says in a rather disorganised speech; the Sting reports live from World Economic Forum 2015 in Davos

What just happened? 5 themes from the COP24 climate talks in Poland

More bank bailouts at taxpayers’ expenses

EP wants data protection guaranteed before allowing fingerprint exchange with UK

Business growth is key to post-pandemic recovery

A new paradigm for collaboration: mission-based ecosystems

Africa is ‘on the rise’, says UN chief Guterres, urging collaboration for better future

MEPs urge UK to break current deadlock

Gender equality and medicine in the 21st century: an equity unachieved

Commission supports Member States in tackling coronavirus hotspots with offer of four million additional doses of BioNTech-Pfizer vaccine to be delivered this month

These 4 companies are turning food waste into cosmetics, clothing and more

Ahead of State of the Union the European Youth Forum highlights lack of action on youth employment

More international support needed to curb deadly measles outbreak in DR Congo

White Coat, Stained red

Gas pipeline in the European Union. (Copyright: EU, 2012 / Source: EC - Audiovisual Service / Photo: Ferenc Isza)

EU Investment Bank approves € 1.5bn loan for Trans Adriatic Pipeline (TAP)

COVID-19 has accelerated India’s digital reset

Commission celebrates the 30th anniversary of the Jean Monnet Activities promoting European studies worldwide

Meet the Seed Warrior: the man on a mission to rescue India’s rice diversity

UN rights chief ‘extremely concerned’ over deadly crackdown on protesters in Iran

Amid COVID-19 constraints, UN women’s commission meets to push gender equality forward

COVID-19, higher education and the impact on society: what we know so far and what could happen

As rural communities age, their public transport is shrinking. It’s time to fix this

Why the future of food must be blue as well as green

The digital revolution will transform the steel industry

ILO: Unemployment to increase by 8.1 million in 2013-2014

Central Mali: Top UN genocide prevention official sounds alarm over recent ethnically-targeted killings

Eco-anxiety during the Pandemic

GSMA Mobile 360 – Africa on 16-18 July 2019, in association with The European Sting

Destroying nuclear waste to create clean energy? It can be done

More Stings?

Advertising

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s